Últimas noticias sobre X4 Pharmaceuticals (NASDAQ:XFOR) Bolsa

X4 PHARMACEUTICALS INC

X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

ALTG

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CARM

CNCK

CRGX

FBNC

MGOL

NAOV

NATR

OFIX

RNGR

SLXN

TSLA

VREX

XFOR

Meta sube en la preapertura tras superar expectativas. Descubre qué otras acciones están registrando fuertes movimientos hoy.

Acciones de Meta Platforms (META) están cotizando al alza; 20 acciones que se mueven en el premercado de EE.UU.

X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc Warrants (12/04/2024)

XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) is down 1% after a U.S. District Judge rejected a proposed $50 million settlement between Ripple Labs and the U.S. SEC. Despite this legal setback, several crypto analysts see signs of <a href="https://www.benzinga.com/money/ripple-xrp-price-prediction">a bullish reversal forming</a>.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.42</td>
<td>$4.9 billion</td>
<td>-1.3%</td>
<td>+3.8%</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$104,362.42</td>
<td>$2.07 trillion</td>
<td>+1.2%</td>
<td>+1.5%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,590.27</td>
<td>$312.8 billion</td>
<td>+1.2%</td>
<td>+12.5%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Prominent trader Dark Defender <a href="https://x.com/DefendDark/status/1923325805473800250">said</a> XRP has completed its final correction wave on the 4-hour chart. 
He now anticipates a move toward $2.55, with the ultimate short-term target set at $3.333. His chart marks key levels:
<ul class="wp-block-list">
<li>Support: $2.3502 and $2.2222</li>
<li>Resistance: $2.58 and $3.3333</li>
</ul>
Meanwhile, trader Scofield echoed optimism, calling the current structure "great" for bulls.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> Looks great now <a href="https://t.co/thEUjpZefI">pic.twitter.com/thEUjpZefI</a>
&mdash; Scofield (@Crypto_Scofield) <a href="https://twitter.com/Crypto_Scofield/status/1923352926761672753?ref_src=twsrc%5Etfw">May 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another analyst, Cryptoinsightuk, <a href="https://x.com/Cryptoinsightuk/status/1923278829407080861">highlighted</a> that XRP's price is unfolding exactly as he predicted. 
While noting there are no guarantees, he believes the setup looks solid, and a bullish reaction here could confirm continuation to the upside. "The stage is set," he said, now waiting for confirmation from market momentum.
Statistics: According to Coinglass, XRP saw $17.32 million in total liquidations over the last 24 hours, with $14.85 million from long positions—indicating traders may have overextended their bets too early.
On-chain tracker Whale Alert spotted two massive XRP transactions on May 16:
<ul class="wp-block-list">
<li>100 million XRP (around $240 million) <a href="https://x.com/whale_alert/status/1923285370461888949">moved</a> <a href="https://x.com/whale_alert/status/1923285370461888949">between</a> unknown wallets</li>
<li>Another 94.3 million XRP (around $232.8 million) <a href="https://x.com/whale_alert/status/1923008301433839928">transferred</a>, again between undisclosed wallets</li>
</ul>
Community News: Judge Analisa Torres <a href="https://x.com/FilanLaw/status/1923075612299649405">dismissed</a> the proposed $50 million Ripple-SEC settlement, ruling that both parties failed to meet the legal requirements to amend the prior final judgment. 
The original $125M penalty and injunction imposed in August 2024 remain in place—for now. The decision adds more uncertainty to one of crypto's most watched legal showdowns.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45468089/bitcoins-dominance-hits-resistance-is-the-eth-xrp-doge-rally-coming">Bitcoin&#8217;s Dominance Hits Resistance: Is The ETH, XRP, DOGE Rally Coming?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$ETH

$XRP

XRP Drops 1%: Why Is It Going Down?

RBC Capital analyst Elvira Scotto reiterates Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) with a Outperform and maintains $63 price target.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on Williams Companies, Maintains $63 Price Target

WIIM

BTDR

Bitdeer Technologies Group shares are trading higher after Needham raised its price target on the stock from $13 to $17. Also, Rosenblatt raised its price target on the stock from $15 to $20.

RBC Capital analyst Logan Reich reiterates Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Outperform and maintains $95 price target.

SBUX

RBC Capital Reiterates Outperform on Starbucks, Maintains $95 Price Target

Wall Street fought for a fifth consecutive day of gains on Friday, with major indexes edging slightly higher by midday in New York as investors continued to digest the week's significant trade breakthroughs and <a href="https://www.benzinga.com/news/econ-s">recalibrate their economic expectations.</a>
The S&amp;P 500 rose 0.1% to 5,925, its highest level since early March, while the Nasdaq 100 held firm after a strong prior session. Gains were broad but cautious as markets balanced optimism over de-escalating tariffs with growing macro concerns. 
Healthcare stocks rebounded from recent underperformance, buoyed by a rally in Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), while the energy sector lagged as crude prices cooled.
The U.S. dollar surged after the <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45470155/consumer-sentiment-crashes-to-5-year-lows-as-inflation-fears-reach-1981-levels">University of Michigan's consumer sentiment report</a> delivered one of the bleakest stagflationary signals in recent decades. 
The headline Consumer Sentiment Index dropped to its lowest level since June 2020, while the Consumer Expectations subindex hit levels not seen since 1980. Year-ahead inflation expectations soared to 7.3%, the highest since late 1981. 
The spike in inflation fears rattled rate-cut bets. Fed funds futures slashed the odds of a June interest rate cut to just 5%, effectively pricing out any move next month. 
Markets now fully price the first rate cut only by October 2025, with a second possibly arriving in December.
Treasury yields rose as bond prices fell, with the 30-year yield rising back to 4.90%, following the dismal sentiment data. The combination of rising yields and a stronger dollar weighed heavily on gold, which dropped 1.8% and is headed for its worst weekly performance since November 2024. 
In crypto, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) bounced back and reclaimed the $104,500 level. 
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,103.26</td>
<td>0.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,932.74</td>
<td>0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,424.05</td>
<td>0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,350.21</td>
<td>0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:15 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.2% up to $591.88.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.2% to $424.32.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;edged 0.1% up $520.03.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.4% to $209.16.</li>
<li>The&nbsp;Health Care&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) outperformed, up 1%; the&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.5%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
<ul class="wp-block-list">
<li>Applied Materials inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) fell 6.1% following a miss in revenue forecasts and revised guidance amid trade challenges with China. </li>
<li>Take-Two Interactive Software inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) fell 2% after missing earnings expectations last quarter. </li>
</ul>
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45472025/loebs-third-point-exits-meta-tesla-rotates-into-staples-telecom-industrials">Loeb&#8217;s Third Point Exits Meta, Tesla, Rotates Into Staples, Telecom, Industrials </a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

AMAT

SPDR Dow Jones Industrial Average ETF Trust

GLOB

TTWO

Select Sector SPDR-Consumer Discretionary

Stocks Fight For Fifth Day Of Gains, Dollar Rebounds As Inflation Fears Go Haywire: What's Driving Markets Friday?

Insider Trades

UnitedHealth Group Form4 Filing Shows John H Noseworthy Bought 300 Shares At An Average Price Of $312.16/Share

<a href="https://www.yuan.com.tw/newscontent/164" title="https://www.yuan.com.tw/newscontent/164">https://www.yuan.com.tw/newscontent/164</a>

NVDA

'YUAN Unveils Next-Gen AI Video Processing Platform with NVIDIA Jetson Orin At GTC 2025' - YUAN

Trading Ideas

Live On CNBC, Stephanie Link Announces Bought More UnitedHealth Group

AAPL

Reuters Reports Apple Spokesperson Says Asked Epic Sweden To Resubmit App Update Without Including The Us Storefront Of The App Store; Did Not Take Any Action To Remove Live Version Of Fortnite From Alternative Distribution Marketplaces

<a href="https://www.fcc.gov/transactions/verizon-frontier" title="https://www.fcc.gov/transactions/verizon-frontier">https://www.fcc.gov/transactions/verizon-frontier</a>
&nbsp;
<a href="https://docs.fcc.gov/public/attachments/DA-25-421A1.pdf" title="https://docs.fcc.gov/public/attachments/DA-25-421A1.pdf">https://docs.fcc.gov/public/attachments/DA-25-421A1.pdf</a>
&nbsp;

FYBR

Federal Communications Commission Approves Verizon's $20B Acquisition Of Frontier Communications After Verizon Drops Diversity Policies

BMO Capital analyst Simeon Siegel maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Outperform and raises the price target from $70 to $75.

BIRK

BMO Capital Maintains Outperform on Birkenstock Holding, Raises Price Target to $75

UnitedHealth Group Form4 Filing Shows Timothy P. Flynn Bought 1,533 Shares At An Average Price Of $320.80/Share

Raymond James analyst Andrew Marok reiterates Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) with a Outperform and raises the price target from $240 to $250.

Raymond James Reiterates Outperform on Take-Two Interactive, Raises Price Target to $250

UnitedHealth Group Form4 Filing Shows Kristen Gil Bought 3,700 Shares At An Average Price Of $271.17/Share

Raymond James analyst Alexander Sklar maintains Karooooo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KARO#NASDAQ">KARO</a>) with a Outperform and raises the price target from $51 to $58.

KARO

Raymond James Maintains Outperform on Karooooo, Raises Price Target to $58

Raymond James analyst Brian Peterson maintains Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) with a Outperform and lowers the price target from $83 to $65.

DOCS

Raymond James Maintains Outperform on Doximity, Lowers Price Target to $65

RBC Capital analyst Scott Hanold reiterates Plains All American (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) with a Sector Perform and maintains $20 price target.

RBC Capital Reiterates Sector Perform on Plains All American, Maintains $20 Price Target

Raymond James analyst Tim Thein maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Outperform and raises the price target from $530 to $560.

Raymond James Maintains Outperform on Deere, Raises Price Target to $560

Live On CNBC, Steve Weiss Announces Sold SPDR Select Sector Fund - Energy Select Sector Position

Raymond James analyst Robert Dodd maintains Crescent Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCAP#NASDAQ">CCAP</a>) with a Outperform and lowers the price target from $20 to $17.

CCAP

Raymond James Maintains Outperform on Crescent Capital BDC, Lowers Price Target to $17

Press Releases

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Health Care

General

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

Earnings

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Reverse Stock Split

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host  Conference Call and Webcast on May 1, 2025

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

Comments

X4 Pharmaceuticals

Noticias

Últimas noticias sobre X4 Pharmaceuticals (NASDAQ:XFOR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL